Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05381805

ISOLATION 2.0: a Multicenter Clinical Care and Research Platform

Treatment recommendations and guidelines for patients with atrial fibrillation (AF) are continuously changing. The role of catheter ablation in the treatment of AF increases and the techniques of the procedures are improving unceasingly. Responding to and evaluating the effect of these changes requires careful examination of this patient population and procedure outcomes. The aim is to create a clinical characterization platform for patients scheduled for AF ablations with the purpose to optimize health care processes and related translational research.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

About this study

Study design: Prospective cohort study and research platform of patients referred for AF ablation. Clinical characteristics and results of routine tests and procedures before, during and after AF ablation are collected. In addition, the following (non-standard) tests are performed: extended surface electrocardiogram (extECG), extended rhythm monitoring, biomarker testing, genetic analysis, and questionnaires. In subgroups of patients transesophageal electrocardiogram (TE-ECG), epicardial electroanatomical mapping and/or left atrial appendage (LAA) biopsy is performed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older;
  • Documented atrial fibrillation;
  • Referred for any type of AF ablation: catheter ablation, stand-alone surgical AF ablation, surgical AF ablation concomitant with cardiac surgery, hybrid AF ablation, or redo AF ablation;
  • Able and willing to provide written informed consent.

Exclusion criteria

  • Conditions preventing the patient from adhering from the study protocol;
  • Emergency procedures.

A subject who meets any of the following criteria will be excluded from the subset in whom additional consent for transesophageal ECG-imaging is asked:

  • Severe allergic reaction against contrast agents used in the CT- or MRI-protocol
  • Severe allergic reaction against body surface electrodes

A subject who meets any of the following criteria will be excluded from the subset in whom additional consent for transesophageal ECG (TE-ECG) is asked:

  • Status after esophageal or gastric surgery

A subject who meets any of the following criteria will be excluded from the subset in whom additional consent for Cardiovascular Magnetic Resonance (ISOLATION CMR) is asked:

  • Contraindication to MRI

A subject who meets any of the following criteria will be excluded from the subset in whom additional consent for concomitant hybrid ablation of atrial fibrillation (COMBAT-AF) is asked:

  • Prior catheter or surgical AF ablation.

Specific exclusion criteria for epicardial mapping (only applicable for patients undergoing hybrid or surgical AF ablation):

  • Chronic obstructive pulmonary disease (COPD) Gold 11, 111, or IV;
  • Heart failure, currently in New York Heart Association (NYHA) class Ill or IV;
  • Any other pulmonary, cardiac, or other condition that may compromise a safe conduct of epicardial mapping in the opinion of the treating physician or investigator, taking the prolonged duration of single lung ventilation into account.

Treatment and study plan

Primary outcomes

  1. Ablation success

    Time frame: 12 months

    Freedom from documented recurrence of atrial arrhythmia after 12 months. Recurrences in the first 3 months after the index procedure (blanking period) are exempted.

Secondary outcomes

  1. Time to recurrence of AF or other atrial arrhythmia after the blanking period.

    Time frame: 3 to 24 months

    Time to recurrence of AF or other atrial arrhythmia after the blanking period of 3 months.

  2. Early recurrences of AF or other atrial arrhythmia

    Time frame: 0 to 3 months

    Defined as any episode of documented arrhythmia during the blanking period, defined as within 3 months

  3. Number of participants with disease progression to persistent or permanent AF.

    Time frame: 0 to 24 months

    Disease progression to persistent or permanent AF. Persistent AF is defined as AF that lasts longer than 7 days. Permanent AF can't be corrected with treatments.

  4. Use of antiarrhythmic drugs (AADs) one year after ablation.

    Time frame: 0 to 24 months

    Use of antiarrhythmic drugs (AADs) one year after ablation

  5. Interleukin 6 (IL-6) level

    Time frame: 0 to 24 months

    Change in circulating biomarker for substrate quantification.

  6. Pro-brain natriuretic peptide 2 (pro-BNP2) level

    Time frame: 0 to 24 months

    Change in circulating biomarker for substrate quantification.

  7. Fibroblast growth factor 23 (FGF-23) level

    Time frame: 0 to 24 months

    Change in circulating biomarker for substrate quantification.

  8. Dickkopf-related protein 3 (DKK-3) level

    Time frame: 0 to 24 months

    Change in circulating biomarker for substrate quantification.

  9. Angiopoietin 2 (ANG-2) level

    Time frame: 0 to 24 months

    Change in circulating biomarker for substrate quantification.

  10. Endothelial cell-specific molecule 1 (ESM-1) level

    Time frame: 0 to 24 months

    Change in circulating biomarker for substrate quantification.

  11. Insulin-like growth factor-binding protein 7 (IGFBP-7) level

    Time frame: 0 to 24 months

    Change in circulating biomarker for substrate quantification.

  12. Bone morphogenetic protein 10 (BMP-10) level

    Time frame: 0 to 24 months

    Change in circulating biomarker for substrate quantification.

  13. Redo procedures

    Time frame: 0 to 24 months

    Defined as repeated ablation procedure with the goal to prevent recurrence of AF or reduce the AF burden after one or more previous attempts to achieve the same goal.

  14. Number of veins with pulmonary vein reconnection at redo procedure.

    Time frame: 0 to 24 months

    Number of veins with pulmonary vein reconnection at redo procedure.

  15. Major adverse cardiovascular events (MACE).

    Time frame: 0 to 24 months

    Major adverse cardiovascular events (MACE).

  16. Procedure time

    Time frame: Intraoperative

    Defined as skin-to-skin time (time from initial femoral vein puncture to time of removal of sheaths).

Study contacts

Contact information is provided by the study sponsor or research team.

Dominique Verhaert, MD

CONTACT

[email protected]

Zarina Habibi, MD

CONTACT

[email protected]

+31-43-3881200

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Collaborators

  • Maastricht University

Registry information

Official study title

Intensive (Pre)Clinical Characterization of Patients undergOing Atrial fibrillATion ablatlON: a Multicenter Clinical Care and Research Platform

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
May 19, 2022
Registry last updated
May 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.